Crohn's Disease and Colitis Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- A treating doctor must decide that the person is appropriate for biologic treatment and has prescribed guselkumab in line with the officially approved uses for this medicine, and the person must be enrolled in the trial before or on the day of their first dose.
- The person must have a confirmed diagnosis of moderate-to-severe ulcerative colitis (UC) or Crohn's disease (CD) recorded in their medical records.
- The person must sign an agreement/consent form that allows the trial team to check their source data, in line with local requirements.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- The person has a medical reason that makes guselkumab unsuitable for them according to the medicine's official label.
- The person is currently taking part in another clinical study that involves a medical intervention.
- The person has previously been treated with a type of medicine called an IL-23 inhibitor, which includes guselkumab (Tremfya), risankizumab (Skyrizi), or mirikizumab (Omvoh) — though people who have previously used ustekinumab may still be considered.
- The person has already been through more than four different advanced treatments for inflammatory bowel disease, including biologics and/or small molecule medicines.
- The person is not able to give their own informed consent to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen-Cilag Pharma GmbH Clinical Trial, Janssen-Cilag Pharma GmbH
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Persistence with Guselkumab Treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.